Status:
ENROLLING_BY_INVITATION
Application of Integrated Proteomic and Serum Metabolomic Analysis in Assessing the Efficacy and Prognosis of TACE Combined With Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
Application of Integrated Proteomic and Serum Metabolomic Analysis in Efficacy and Prognosis Assessment: A multi-omics analysis based on gut microbiota to evaluate the predictive value of microbial-de...
Detailed Description
This study is a prospective, observational study based on real-world data. It prospectively and continuously collects data from patients with unresectable hepatocellular carcinoma who have received TA...
Eligibility Criteria
Inclusion
- Age ≥ 18 years.
- Histologically or clinically diagnosed with hepatocellular carcinoma (HCC).
- Classified as BCLC stage B/C, not suitable for surgical resection or liver transplantation.
- Planned or already receiving TACE combined with tiragolumab and first-line targeted therapy for liver cancer.
- Not participating in other clinical studies.
- Able to obtain imaging evaluation data and other clinical records during treatment.
Exclusion
- Known fibrolamellar HCC, sarcomatoid HCC, or mixed hepatocellular-cholangiocarcinoma histology.
- Tumors involving the main portal vein or inferior vena cava.
- Use of antibiotics within one month before treatment.
- History of other malignancies.
Key Trial Info
Start Date :
February 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06540508
Start Date
February 1 2023
End Date
May 1 2025
Last Update
August 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100021